Celgene Corporation Elects Rodman L. Drake to Board of Directors

     SUMMIT, N.J., April 20 /PRNewswire-FirstCall/ -- Celgene Corporation
(Nasdaq: CELG) announced Thursday, April 20, the election of Rodman L. Drake to
the Company's Board of Directors. Mr. Drake is an experienced corporate director
and former CEO with more than 30 years of diverse consulting and executive
management experience. He will serve as a member of the Nominating and Audit
Committees of the Celgene Board of Directors. Mr. Drake has spent most of his
career in executive level positions such as Co-Chairman of KMR Power Company, a
developer of independent power projects internationally, Chief Executive Officer
and Managing Director of Cresap McCormick and Paget, a leading international
management consulting firm, and President of The Mandrake Group, a consulting
firm specializing in strategy and organizational design.

     Mr. Drake received a B.A. degree from Yale University and an M.B.A. from
Harvard Business School.

     "Celgene will benefit substantially from Rodman's extensive expertise,"
said John W. Jackson, Chairman and Chief Executive Officer of Celgene
Corporation. "He is a welcomed addition to the Board and we look forward to his
valuable contributions."

     About Celgene

     Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global biopharmaceutical company engaged primarily in the discovery, development
and commercialization of novel therapies for the treatment of cancer and
inflammatory diseases through gene and protein regulation. For more information,
please visit the Company's website at http://www.celgene.com.

     This release contains certain forward-looking statements which involve
known and unknown risks, delays, uncertainties and other factors not under the
Company's control, which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance or other
expectations implied by these forward-looking statements. These factors include
results of current or pending research and development activities, actions by
the FDA and other regulatory authorities, and those factors detailed in the
Company's filings with the Securities and Exchange Commission such as 10K, 10Q
and 8K reports.

SOURCE  Celgene Corporation
    -0-                             04/20/2006

     /CONTACT: Robert J. Hugin, Senior VP and CFO, +1-908-673-9102, or Brian P.
Gill, Senior Director of PR and IR, +1-908-673-9530, both of Celgene
Corporation/

     /First Call Analyst: /
     /FCMN Contact: mblackstone@celgene.com /
     /Web site:  http://www.celgene.com /
     (CELG)